secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2026-10-09T20:30:14+00:00
Accession:  0001193125-26-419154
Event type: regulatory
Sentiment:  negative
Materiality: 0.72
Item codes: 3.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Alaunos Therapeutics gets Nasdaq delisting notice over $2.5M equity rule; plans hearing
--------------------------------------------------------------------------------

- Nasdaq staff notified Alaunos on Oct. 5, 2026 that its securities are subject to delisting for failing Listing Rule 5550(b)(1), the $2,500,000 minimum stockholders' equity requirement.
- Company first received non-compliance notice on April 9, 2026 and submitted a timely plan to regain compliance; that plan was not accepted.
- Alaunos plans to timely request a hearing before the Nasdaq Hearings Panel, which stays suspension or delisting at least until the hearing and any extension expires.
- Company is working with a financial advisor to evaluate strategic alternatives and potential transactions to regain listing compliance; no assurance any deal will be signed or completed.
- Common stock trades on Nasdaq Capital Market under symbol TCRT; signed by CEO Holger Weis, dated October 9, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000119312526419154/0001193125-26-419154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000119312526419154/tcrt-20261005.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-419154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer